DEEPBLUE Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent was awarded CE 1434 Certificate

Oct 11, 2021

On October 8, 2021, the novel coronavirus (COVID-19) neutralizing antibody (double antigen sandwich) detection reagent (colloidal gold method) independently developed by Anhui Deepblue Medical successfully obtained the CE1434 certificate, which meets the relevant EU requirements and market standards. Entry qualification.

CE 1434 self-test certification is not only difficult, long-term, and strict, but also a test of comprehensive strength. In July 2021, DeepBlue Medical's novel coronavirus (COVID-19) antigen detection reagent obtained the CE1434 certificate, and the new coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent obtained the CE1434 certificate. The strong recognition of the research and development technology of viral in vitro diagnostic reagents has far-reaching significance for the development of the international market and brand expansion.

The novel coronavirus (COVID-19) neutralizing antibody (double-antigen sandwich) detection reagent independently developed by Anhui Deepblue Medical has obtained the CE1434 certificate, which can not only be freely sold in the 31 EU member states, but also bring more convenience to the global anti-epidemic. Check resources. The blessing of the CE1434 certificate also reflects the European market's recognition of the performance and user experience of DeepBlue Medical products, and it is also a high affirmation of the comprehensive strength of DeepBlue Medical.

At present, most countries and regions in the world have gradually shifted from nucleic acid testing during the outbreak to neutralizing antibody testing to assess whether immunity is protected. The Deepblue Medical Novel Coronavirus (COVID-19) Neutralizing Antibody (Double Antigen Sandwich) Detection Reagent can simply, quickly and effectively reflect the presence and level of neutralizing antibodies after vaccination, and play a guiding role in the need for booster vaccination.

In the future, Deepblue Medical will continue to adhere to the vision of "based on the health industry, give full play to the advantages of science and technology, and build a health industry aircraft carrier", strive to develop better products, and contribute to the global epidemic prevention and control and the evaluation of the immune effect of vaccines!

SEND A MESSAGE
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!
  • # Address

    Pearl Industrial Park,106 Innovation Avenue, High-Tech Development Zone / No. 777 Jimingshan Road, High-Tech Development Zone, 230088 Hefei, Anhui, PEOPLE'S REPUBLIC OF CHINA

  • # Call Us

    Tel : +86-551-65326797

  • # email us

    Email : sales@dbluemedical.com

top
Leave A Message
Leave A Message
If you have questions or suggestions,please leave us a message,we will reply you as soon as we can!

Home

Product

Contact